Medtronic plc. (NYSE:MDT)‘s stock had its “buy” rating reissued by investment analysts at CIBC in a report issued on Friday.

Several other equities analysts have also commented on MDT. Needham & Company LLC reissued a “buy” rating and issued a $95.00 target price (up previously from $91.00) on shares of Medtronic plc. in a report on Thursday. Zacks Investment Research lowered Medtronic plc. from a “hold” rating to a “sell” rating in a report on Tuesday. Vetr lowered Medtronic plc. from a “buy” rating to a “hold” rating and set a $80.67 target price on the stock. in a report on Thursday, February 16th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Medtronic plc. in a report on Wednesday, March 22nd. Finally, Evercore ISI increased their target price on Medtronic plc. from $88.00 to $88.50 and gave the company an “outperform” rating in a report on Wednesday, April 19th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $87.33.

Analyst Recommendations for Medtronic plc. (NYSE:MDT)

Shares of Medtronic plc. (NYSE:MDT) traded down 0.57% during mid-day trading on Friday, reaching $85.09. The company’s stock had a trading volume of 4,791,850 shares. Medtronic plc. has a one year low of $69.35 and a one year high of $89.27. The stock has a market cap of $116.48 billion, a P/E ratio of 30.04 and a beta of 0.97. The stock has a 50 day moving average of $82.46 and a 200-day moving average of $78.52.

Medtronic plc. (NYSE:MDT) last posted its quarterly earnings data on Thursday, May 25th. The medical technology company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. Medtronic plc. had a return on equity of 12.36% and a net margin of 14.63%. The business had revenue of $7.92 billion for the quarter, compared to analyst estimates of $7.86 billion. During the same quarter in the prior year, the company earned $1.27 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts expect that Medtronic plc. will post $4.96 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Medtronic plc. (MDT) Stock Rating Reaffirmed by CIBC” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/26/medtronic-plc-mdt-stock-rating-reaffirmed-by-cibc.html.

In related news, EVP Hooman Hakami sold 52,316 shares of the stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $82.33, for a total transaction of $4,307,176.28. Following the completion of the transaction, the executive vice president now directly owns 73,800 shares of the company’s stock, valued at $6,075,954. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Hoedt Rob Ten sold 50,757 shares of the stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $81.58, for a total transaction of $4,140,756.06. Following the transaction, the executive vice president now directly owns 59,392 shares of the company’s stock, valued at $4,845,199.36. The disclosure for this sale can be found here. Insiders have sold 198,073 shares of company stock valued at $16,315,832 over the last three months. 0.25% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of MDT. Jackson Grant Investment Advisers Inc. boosted its position in shares of Medtronic plc. by 0.3% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 2,920 shares of the medical technology company’s stock worth $235,000 after buying an additional 9 shares during the period. Hudock Capital Group LLC boosted its position in shares of Medtronic plc. by 0.6% in the first quarter. Hudock Capital Group LLC now owns 2,184 shares of the medical technology company’s stock worth $175,000 after buying an additional 12 shares during the period. Delta Asset Management LLC TN boosted its position in shares of Medtronic plc. by 0.4% in the first quarter. Delta Asset Management LLC TN now owns 3,713 shares of the medical technology company’s stock worth $299,000 after buying an additional 13 shares during the period. Bollard Group LLC boosted its position in shares of Medtronic plc. by 0.4% in the first quarter. Bollard Group LLC now owns 3,637 shares of the medical technology company’s stock worth $293,000 after buying an additional 14 shares during the period. Finally, Tarbox Group Inc. boosted its position in shares of Medtronic plc. by 0.4% in the first quarter. Tarbox Group Inc. now owns 5,180 shares of the medical technology company’s stock worth $417,000 after buying an additional 20 shares during the period. 82.71% of the stock is owned by hedge funds and other institutional investors.

About Medtronic plc.

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

12 Month Chart for NYSE:MDT

Receive News & Ratings for Medtronic plc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc. and related companies with MarketBeat.com's FREE daily email newsletter.